SCHEMBL22545459

SCHEMBL22545459

CC(C)COC(=O)CN=S(=O)(c1cccc(C(F)F)c1)c1cccc(C(F)F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.35
▸ TSHR P16473 2/20 0.35
▸ KAT6A Q92794 1/20 0.33
▸ CA2 P00918 4/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ NPY1R P25929 1/20 0.32
▸ NPY2R P49146 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ HSD11B1 P28845 1/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22545448 0.84 TSHR (0.41) RAB9AALDH1A1TSHRTDP1L3MBTL1
SCHEMBL22545267 0.83 NPSR1 (0.45) ALDH1A1CA2MAPTNPSR1CA1
SCHEMBL22527632 0.83 PTPRC (0.36) CA2L3MBTL1CA1
SCHEMBL22545577 0.81 HDAC8 (0.41) RAB9AALDH1A1TSHRKAT6A
SCHEMBL25678174 0.79 CACNA1F (0.41) RAB9AALDH1A1CA2MAPTMEN1
SCHEMBL22545513 0.77 CA2 (0.35) RAB9AALDH1A1TSHRKAT6ACA2
SCHEMBL22545460 0.77 AAK1 (0.32) —
SCHEMBL16642002 0.66 PSIP1 (0.50) ALDH1A1TSHRCA2HSD11B1
SCHEMBL22181477 0.66 ALDH1A1 (0.46) ALDH1A1CA2
SCHEMBL28584804 0.66 TSHR (0.52) ALDH1A1TSHRCA2TDP1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331745-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES NOVO NORDISK AS (DK) 2023-10-19 — — US disclosed
EP-3707145-B1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES NOVO NORDISK AS (DK) 2023-06-21 — — EP disclosed
US-11186595-B2 Glucose-sensitive albumin-binding derivatives NOVO NORDISK A/S (DK) 2021-11-30 — — US disclosed
US-20200325160-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES NOVO NORDISK A/S (DK) 2020-10-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331745-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES ALB, DBI, FABP4 RAB9A 2780/4885ALDH1A1 1240/4885TSHR 3575/4885
US-11186595-B2 Glucose-sensitive albumin-binding derivatives ALB, GPR119, MLX RAB9A 1733/4885ALDH1A1 456/4885TSHR 1295/4885
US-20200325160-A1 GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES ALB, GPR119, MLX RAB9A 1733/4885ALDH1A1 456/4885TSHR 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback